Home › Therapeutic areas › Oncology
Oncology (107 companies · 52 conditions)
Conditions
Non-Small Cell Lung Cancer 40 Colorectal Cancer 27 Pancreatic Cancer 27 Breast Cancer 24 Prostate Cancer 22 Solid Tumors 22 Glioblastoma 18 Acute Myeloid Leukemia 16 Lymphoma 16 Melanoma 16 Ovarian Cancer 16 Multiple Myeloma 12 Bladder Cancer 11 Cholangiocarcinoma 10 Gastric Cancer 10 Head and Neck Cancer 10 Renal Cell Carcinoma 10 Hepatocellular Carcinoma 9 Small Cell Lung Cancer 8 Endometrial Cancer 7 Cutaneous Squamous Cell Carcinoma 6 Myelofibrosis 5 Acute Lymphoblastic Leukemia 4 Diffuse Large B-Cell Lymphoma 4 Myelodysplastic Syndrome 4 Brain Metastases 3 Gastroesophageal Junction Cancer 3 Mesothelioma 3 Neuroendocrine Tumors 3 Sarcoma 3 Waldenstrom Macroglobulinemia 3 Acute Leukemia 2 Cervical Cancer 2 Chronic Lymphocytic Leukemia 2 Esophageal Cancer 2 Gastrointestinal Stromal Tumors 2 Lung Cancer 2 Meningioma 2 Merkel Cell Carcinoma 2 Pediatric Solid Tumors 2 T-Cell Lymphoma 2 Anal Squamous Cell Carcinoma 1 Atypical Teratoid/Rhabdoid Tumor 1 Rare Basal Cell Carcinoma 1 Chronic Myeloid Leukemia 1 Desmoid Tumors 1 Rare Hodgkin Lymphoma 1 Large Cell Neuroendocrine Carcinoma 1 Rare Nasopharyngeal Carcinoma 1 Neurofibromatosis Type 1 1 Skin Cancer 1 Thyroid Cancer 1
Companies
| Ticker | Company | Therapeutic areas | In Oncology | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 7 | Phase 2 | $69.0M | 9 |
| ACTU | Actuate Therapeutics | Oncology | 3 | Phase 2 | $7.9M | 4 |
| ADAG | Adagene | Oncology | 6 | Phase 2 | $134M | 10 |
| ADCT | ADC Therapeutics | Oncology | 5 | Approved | $202M | 5 |
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 1 | Phase 1 | $28.6M | 8 |
| AKTS | Aktis Oncology | Oncology | 8 | Phase 1 | $880M | 10 |
| ALDX | Aldeyra Therapeutics | DermatologyOncology+1 | 1 | NDA Submitted | $38.3M | 5 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 7 | Phase 2 | $360M | 10 |
| DRTS | Alpha Tau Medical | Oncology | 6 | Phase 2 | $1.27B | 6 |
| ANTX | AN2 Therapeutics | HematologyInfectious Disease+1 Rare | 1 | Phase 2 | $151M | 6 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 2 | Approved | $1.39B | 9 |
| ANIX | Anixa Biosciences | Oncology | 3 | Phase 1 | $111M | 3 |
| APVO | Aptevo Therapeutics | Oncology | 5 | Phase 1 | $2.2M | 8 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 4 | Phase 3 | $2.63B | 8 |
| ARTV | Artiva Biotherapeutics | Oncology | 5 | — | $203M | 6 |
| ARVN | Arvinas | NeurologyOncology Rare | 6 | Approved | $420M | 10 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 8 | Approved | $341M | 12 |
| BCAX | Bicara Therapeutics | Oncology | 4 | Phase 2 | $572M | 4 |
| BCYC | Bicycle Therapeutics | Oncology | 3 | Phase 2 | $253M | 4 |
| BMEA | Biomea Fusion | MetabolicOncology | 1 | Phase 2 | $41.1M | 4 |
| BDTX | Black Diamond Therapeutics | Oncology | 3 | Phase 2 | $99.7M | 4 |
| BCTX | BriaCell Therapeutics | Oncology | 7 | Phase 3 | $34.5M | 8 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | 6 | Phase 1 | $164M | 6 |
| CCCC | C4 Therapeutics | Oncology | 2 | Phase 2 | $407M | 2 |
| CADL | Candel Therapeutics | Oncology | 3 | Phase 3 | $670M | 4 |
| RNAC | Cartesian Therapeutics | ImmunologyNeurology+1 Rare | 1 | Phase 3 | $230M | 4 |
| CLRB | Cellectar Biosciences | Oncology | 6 | Phase 2 | $11.8M | 6 |
| CGON | CG Oncology | Oncology | 1 | NDA Submitted | $6.79B | 1 |
| COGT | Cogent Biosciences | HematologyOncology Rare | 3 | NDA Submitted | $5.51B | 7 |
| CHRS | Coherus Oncology | Oncology | 4 | Approved | $119M | 4 |
| CMPX | Compass Therapeutics | Oncology | 12 | Phase 2 | $137M | 15 |
| CGEN | Compugen | Oncology | 7 | Phase 3 | $186M | 7 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | 2 | Phase 3 | $889M | 7 |
| CBIO | Crescent Biopharma | Oncology | 8 | Phase 2 | $503M | 10 |
| CRNX | Crinetics Pharmaceuticals | MetabolicOncology Rare | 2 | Approved | — | 6 |
| CUE | Cue Biopharma | ImmunologyOncology | 1 | Phase 2 | $136M | 6 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 3 | NDA Submitted | $728M | 10 |
| CYDY | CytoDyn | NeurologyOncology | 2 | Phase 2 | $338M | 3 |
| CTMX | CytomX Therapeutics | Oncology | 6 | Phase 1 | $477M | 7 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 1 | Phase 3 | $3.59B | 9 |
| EIKN | Eikon Therapeutics | Oncology | 12 | Phase 2 | $320M | 13 |
| ELTX | Elicio Therapeutics | Oncology | 4 | Phase 2 | $42.7M | 6 |
| ELVN | Enliven Therapeutics | Oncology | 1 | Phase 1 | $3.64B | 1 |
| ERAS | Erasca | Oncology | 4 | Phase 1 | $5.04B | 5 |
| EXEL | Exelixis | CardiovascularOncology | 17 | Approved | $17.0B | 23 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 3 | Phase 2 | $224M | 10 |
| FHTX | Foghorn Therapeutics | Oncology | 3 | Preclinical | $111M | 4 |
| FBIO | Fortress Biotech | DermatologyHematology+3 Rare | 2 | Approved | $61.7M | 12 |
| GNLX | Genelux | Oncology | 3 | Phase 3 | $88.7M | 3 |
| GERN | Geron | Oncology | 3 | Approved | $638M | 3 |
| GLSI | Greenwich LifeSciences | Oncology | 1 | Phase 3 | $223M | 1 |
| IDYA | IDEAYA Biosciences | Oncology | 9 | NDA Submitted | $3.02B | 14 |
| IMTX | Immatics | Oncology | 7 | Phase 3 | $968M | 8 |
| IMRX | Immuneering | Oncology | 4 | Phase 3 | $238M | 5 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 12 | Approved | $9.15B | 16 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 10 | Approved | $1.60B | 15 |
| IMNM | Immunome | Oncology Rare | 9 | NDA Submitted | $2.13B | 9 |
| INAB | IN8bio | ImmunologyOncology | 3 | Phase 1 | $10.0M | 4 |
| INBX | Inhibrx Biosciences | Oncology | 5 | NDA Submitted | $1.24B | 6 |
| JANX | Janux Therapeutics | Oncology | 3 | Phase 1 | $1.08B | 4 |
| KAPA | Kairos Pharma | Oncology | 10 | Phase 2 | — | 13 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 10 | Phase 2 | $82.0M | 13 |
| KROS | Keros Therapeutics | NeurologyOncology Rare | 2 | Phase 3 | $184M | 5 |
| KURA | Kura Oncology | MetabolicOncology | 8 | Approved | $647M | 12 |
| LEGN | Legend Biotech | Oncology Rare | 15 | Approved | $4.55B | 17 |
| MAIA | MAIA Biotechnology | Oncology | 4 | Phase 3 | $64.5M | 7 |
| MRKR | Marker Therapeutics | Oncology | 4 | Phase 1 | $14.8M | 4 |
| MDNAF | Medicenna Therapeutics | Oncology | 3 | Phase 2 | $29.5M | 10 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 4 | Phase 2 | $52.8M | 8 |
| MBRX | Moleculin Biotech | Oncology | 6 | Phase 2 | — | 8 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 2 | Phase 2 | $903M | 7 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 3 | Phase 3 | $1.27B | 11 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 5 | Phase 2 | $106M | 7 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 9 | Phase 3 | $1.67B | 13 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 6 | Phase 3 | $719M | 9 |
| OLMA | Olema Pharmaceuticals | Oncology | 3 | Phase 3 | $641M | 3 |
| OMER | Omeros | HematologyNeurology+2 Rare | 1 | Approved | $1.22B | 6 |
| ONCY | Oncolytics Biotech | Oncology | 2 | Phase 2 | $56.1M | 3 |
| OKUR | OnKure Therapeutics | Oncology | 1 | Preclinical | $116M | 2 |
| ORIC | Oric Pharmaceuticals | Oncology | 4 | Phase 3 | $914M | 5 |
| KTTA | Pasithea Therapeutics | NeurologyOncology Rare | 2 | Phase 1 | $19.3M | 4 |
| CATX | Perspective Therapeutics | Oncology | 4 | Phase 1 | $95.9M | 4 |
| PHIO | Phio Pharmaceuticals | Oncology | 3 | Phase 1 | $9.6M | 4 |
| PMVP | PMV Pharmaceuticals | Oncology | 7 | Phase 2 | $67.4M | 7 |
| PYPD | PolyPid | Infectious DiseaseOncology | 1 | NDA Submitted | $125M | 3 |
| PRLD | Prelude Therapeutics | HematologyOncology Rare | 2 | Phase 1 | $287M | 3 |
| TARA | Protara Therapeutics | DermatologyMetabolic+1 Rare | 1 | Phase 3 | $142M | 3 |
| RXRX | Recursion Pharmaceuticals | Oncology | 4 | Phase 2 | $2.19B | 6 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 3 | Approved | $4.11B | 4 |
| RLMD | Relmada Therapeutics | MetabolicNeurology+1 Rare | 1 | Phase 2 | $416M | 4 |
| REPL | Replimune Group | Oncology | 5 | Approved | $2.05B | 5 |
| RVMD | Revolution Medicines | Oncology | 7 | Approved | $41.6B | 11 |
| SANA | Sana Biotechnology | MetabolicOncology | 2 | Phase 1 | $710M | 4 |
| SLS | SELLAS Life Sciences Group | Oncology | 8 | Phase 3 | $1.70B | 9 |
| SMMT | Summit Therapeutics | Oncology | 6 | NDA Submitted | $13.1B | 6 |
| STRO | Sutro Biopharma | Oncology | 3 | Phase 1 | $160M | 4 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 6 | Approved | $852M | 7 |
| TNGX | Tango Therapeutics | Oncology | 4 | Phase 1 | $3.63B | 4 |
| TLX | Telix Pharmaceuticals | Oncology | 20 | Approved | $3.27B | 25 |
| HURA | TuHURA Biosciences | Oncology | 4 | Phase 3 | $104M | 4 |
| TYRA | Tyra Biosciences | MetabolicOncology Rare | 4 | Phase 2 | $1.26B | 5 |
| VSTM | Verastem | Oncology | 5 | Approved | $1.06B | 5 |
| VRCA | Verrica Pharmaceuticals | DermatologyOncology | 1 | Approved | $54.8M | 3 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 8 | Phase 3 | $2.09B | 12 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 16 | Approved | $2.68B | 28 |
| ZNTL | Zentalis Pharmaceuticals | Oncology | 1 | Phase 3 | $123M | 1 |
| ZYME | Zymeworks | OncologyRespiratory | 10 | Approved | $2.10B | 11 |
No companies match.